SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Exelixis, Inc. (EXEL) -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (875)9/29/2012 6:35:13 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 930
 
Roche has disclosed that it intends to evaluate the combination of vemurafenib with GDC-0973 versus vemurafenib in a multicenter, randomized, double-blind, placebo-controlled Phase III trial in previously untreated patients with BRAFV600 mutation positive, unresectable locally advanced or metastatic melanoma.

clinicaltrials.gov



To: scaram(o)uche who wrote (875)9/29/2012 6:36:35 PM
From: scaram(o)uche  Respond to of 930
 
(deleted, duplicate post)